Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Central Venous Catheter Lock Solution (CVCLS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00862966
Recruitment Status : Unknown
Verified March 2009 by University Medical Center, Tuzla.
Recruitment status was:  Not yet recruiting
First Posted : March 17, 2009
Last Update Posted : March 17, 2009
Sponsor:
Information provided by:
University Medical Center, Tuzla

Brief Summary:
The purpose of this study is to determine whether the application of 47% citrate lock solution decreases the incidence of infection and thrombosis of central venous catheter in hemodialysis population.

Condition or disease Intervention/treatment Phase
Bacteremia Other: citrate Other: heparin Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Randomized Control Trial on Citrate as the Central Venous Catheter Lock Solution
Study Start Date : April 2009
Estimated Primary Completion Date : April 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Blood Thinners

Arm Intervention/treatment
Experimental: citrate Other: citrate
comparison of different catheter lock solutions

Active Comparator: heparin Other: heparin
comparison of different lock solutions




Primary Outcome Measures :
  1. lower incidence of infection [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. lower incidence of thrombosis [ Time Frame: 1 year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinical diagnosis of end stage renal disease

Exclusion Criteria:

  • Patients refusing randomization

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00862966


Contacts
Layout table for location contacts
Contact: Goran Imamovic, MD, PhD +387 61 194 131 goran_imamovic@bih.net.ba

Locations
Layout table for location information
Bosnia and Herzegovina
Department of Dialysis
Tuzla, TK, Bosnia and Herzegovina, 75000
Contact: Goran Imamovic, MD,PhD    +387 61 194 131    goran_imamovic@bih.net.ba   
Principal Investigator: Goran Imamovic, MD, PhD         
Sponsors and Collaborators
University Medical Center, Tuzla
Layout table for additonal information
Responsible Party: UNIVERSITY MEDICAL CENTER, Department of Dialysis
ClinicalTrials.gov Identifier: NCT00862966    
Other Study ID Numbers: UMC-02-139
First Posted: March 17, 2009    Key Record Dates
Last Update Posted: March 17, 2009
Last Verified: March 2009
Additional relevant MeSH terms:
Layout table for MeSH terms
Bacteremia
Bacterial Infections
Sepsis
Infection
Systemic Inflammatory Response Syndrome
Inflammation
Pathologic Processes
Heparin
Anticoagulants
Molecular Mechanisms of Pharmacological Action
Fibrinolytic Agents
Fibrin Modulating Agents